Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2013 | 1 | 10-15

Article title

Visfatin: a new player in rheumatic diseases


Title variants

Languages of publication



During the last 50 years the number of overweight and obese people in
developed countries has increased dramatically. The consequences of this
excessive fat accumulation have been associated with a multitude of comorbidities,
mainly related to the cardiovascular system and glucose and
lipid metabolism. However, obesity also has an impact on other diseases,
as an enhancer of certain pathological aspects or as a susceptibility
factor, including certain rheumatic diseases such as rheumatoid arthritis
(RA), osteoarthritis (OA) and systemic lupus erythematosus (SLE). The link
between obesity and these rheumatic diseases has been purported to be
via the action of metabolic factors produced by adipose tissue, adipokines.
Among these adipokines are leptin and adiponectin, which have been
extensively studied. Our knowledge of the role of other relevant newer
adipokines, such as visfatin, in the arthritides is rapidly growing. Therefore,
in this review our aim is to summarize the current literature regarding the
association between visfatin and the most relevant rheumatic diseases.







Physical description


02 - 05 - 2013
14 - 04 - 2013
17 - 06 - 2013


  • Musculoskeletal Research Group,
    Institute of Cellular Medicine,
    4th Floor Catherine Cookson Building,
    The Medical School, Newcastle University,
    Newcastle upon Tyne, NE2 4HH, UK
  • Musculoskeletal Research Group,
    Institute of Cellular Medicine,
    4th Floor Catherine Cookson Building,
    The Medical School, Newcastle University,
    Newcastle upon Tyne, NE2 4HH, UK
  • Osteoarticular pathology laboratory,
    Institute Fundación Jimenez Diaz,
    Fundación Jiménez Díaz,
    Avd. Reyes Católicos,
    Madrid, Spain
  • Osteoarticular pathology laboratory,
    Institute Fundación Jimenez Diaz,
    Fundación Jiménez Díaz,
    Avd. Reyes Católicos,
    Madrid, Spain
  • Osteoarticular pathology laboratory,
    Institute Fundación Jimenez Diaz,
    Fundación Jiménez Díaz,
    Avd. Reyes Católicos,
    Madrid, Spain
  • Musculoskeletal Research Group,
    Institute of Cellular Medicine,
    4th Floor Catherine Cookson Building,
    The Medical School, Newcastle University,
    Newcastle upon Tyne, NE2 4HH, UK


  • [1] Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I.Cloning and characterization of the cDNA encoding a novelhuman pre-B-cell colony-enhancing factor. Mol Cell Biol1994; 14(2):1431-1437.[PubMed]
  • [2] Fukuhara A, Matsuda M, Nishizawa M, Segawa K, TanakaM, Kishimoto K et al. Visfatin: a protein secreted byvisceral fat that mimics the effects of insulin. Science 2005;307(5708):426-430.
  • [3] Terra X, Auguet T, Quesada I, Aguilar C, Luna AM, Hernandez Met al. Increased levels and adipose tissue expression of visfatin inmorbidly obese women: the relationship with pro-inflammatorycytokines. Clin Endocrinol (Oxf) 2012; 77(5):691-698.[Crossref]
  • [4] Aggeloussi S, Theodorou AA, Paschalis V, Nikolaidis MG,Fatouros IG, Owolabi EO et al. Adipocytokine levels inchildren: effects of fatness and training. Pediatr Exerc Sci2012; 24(3):461-471.[PubMed]
  • [5] Li RZ, Ma XY, Hu XF, Kang SX, Chen SK, Cianflone K etal. Elevated visfatin levels in obese children are relatedto proinflammatory factors. J Pediatr Endocrinol Metab2012:1-8.
  • [6] Karbaschian Z, Hosseinzadeh-Attar MJ, Giahi L, Golpaie A,Masoudkabir F, Talebpour M et al. Portal and systemic levelsof visfatin in morbidly obese subjects undergoing bariatricsurgery. Endocrine 2012.[PubMed]
  • [7] Haider DG, Pleiner J, Francesconi M, Wiesinger GF,Muller M, Wolzt M. Exercise training lowers plasma visfatinconcentrations in patients with type 1 diabetes. J ClinEndocrinol Metab 2006; 91(11):4702-4704.[PubMed][Crossref]
  • [8] Wang T, Zhang X, Bheda P, Revollo JR, Imai S, WolbergerC. Structure of Nampt/PBEF/visfatin, a mammalian NAD+biosynthetic enzyme. Nat Struct Mol Biol 2006; 13(7):661-662.[Crossref][PubMed]
  • [9] Normile D. Scientific publishing. Osaka University researchersreject demand to retract Science paper. Science 2007;316(5832):1681.
  • [10] Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M,Kishimoto K et al. Retraction. Science 2007; 318(5850):565.
  • [11] Spinnler R, Gorski T, Stolz K, Schuster S, Garten A, Beck-Sickinger AG et al. The adipocytokine Nampt and its productNMN have no effect on beta-cell survival but potentiateglucose stimulated insulin secretion. PLoS One 2013;8(1):e54106.[Crossref]
  • [12] Uslu S, Kebapci N, Kara M, Bal C. Relationship betweenadipocytokines and cardiovascular risk factors in patientswith type 2 diabetes mellitus. Exp Ther Med 2012; 4(1):113-120.[PubMed]
  • [13] Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, ShinSJ et al. Elevated plasma level of visfatin/pre-B cell colonyenhancingfactor in patients with type 2 diabetes mellitus. JClin Endocrinol Metab 2006; 91(1):295-299.[Crossref][PubMed]
  • [14] Kowalska I, Karczewska-Kupczewska M, Adamska A,Nikolajuk A, Otziomek E, Straczkowski M. Serum visfatinis differentially regulated by insulin and free Fatty acids inhealthy men. J Clin Endocrinol Metab 2013; 98(2):E293-297.[Crossref]
  • [15] Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatinin overweight/obesity, type 2 diabetes mellitus, insulinresistance, metabolic syndrome and cardiovascular diseases:a meta-analysis and systemic review. Diabetes Metab ResRev 2011; 27(6):515-527.[PubMed][Crossref]
  • [16] Lago F, Gomez R, Gomez-Reino JJ, Dieguez C, Gualillo O.Adipokines as novel modulators of lipid metabolism. TrendsBiochem Sci 2009; 34(10):500-510.[PubMed][Crossref]
  • [17] Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines asemerging mediators of immune response and inflammation.Nat Clin Pract Rheumatol 2007; 3(12):716-724.[PubMed][Crossref]
  • [18] Auguet T, Terra X, Porras JA, Orellana-Gavalda JM, MartinezS, Aguilar C et al. Plasma visfatin levels and gene expressionin morbidly obese women with associated fatty liver disease.Clin Biochem 2013; 46(3):202-208.[PubMed][Crossref]
  • [19] Moschen AR, Kaser A, Enrich B, Mosheimer B, TheurlM, Niederegger H et al. Visfatin, an adipocytokine withproinflammatory and immunomodulating properties. JImmunol 2007; 178(3):1748-1758.[Crossref][PubMed]
  • [20] Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F,Gualillo O. What’s new in our understanding of the role ofadipokines in rheumatic diseases? Nat Rev Rheumatol 2011;7(9):528-536.[PubMed][Crossref]
  • [21] Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ et al. Changes in plasma levels of fat-derivedhormones adiponectin, leptin, resistin and visfatin in patientswith rheumatoid arthritis. Ann Rheum Dis 2006; 65(9):1198-1201.[Crossref][PubMed]
  • [22] Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K,Kohno M et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. AnnRheum Dis 2008; 67(4):571-572.[PubMed]
  • [23] Rho YH, Solus J, Sokka T, Oeser A, Chung CP, GebretsadikT et al. Adipocytokines are associated with radiographicjoint damage in rheumatoid arthritis. Arthritis Rheum 2009;60(7):1906-1914.[PubMed][Crossref]
  • [24] Senolt L, Krystufkova O, Hulejova H, Kuklova M, FilkovaM, Cerezo LA et al. The level of serum visfatin (PBEF)is associated with total number of B cells in patients withrheumatoid arthritis and decreases following B cell depletiontherapy. Cytokine 2011; 55(1):116-121.[Crossref][PubMed]
  • [25] Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A.Visfatin levels and intima-media thicknesses in rheumaticdiseases. Clin Rheumatol 2011; 30(6):757-763.[Crossref][PubMed]
  • [26] Straburzynska-Lupa A, Nowak A, Pilaczynska-Szczesniak L,Straburzynska-Migaj E, Romanowski W, Karolkiewicz J et al.Visfatin, resistin, hsCRP and insulin resistance in relation toabdominal obesity in women with rheumatoid arthritis. ClinExp Rheumatol 2010; 28(1):19-24.
  • [27] Klein-Wieringa IR, van der Linden MP, Knevel R,Kwekkeboom JC, van Beelen E, Huizinga TW et al. Baselineserum adipokine levels predict radiographic progression inearly rheumatoid arthritis. Arthritis Rheum 2011; 63(9):2567-2574.[Crossref]
  • [28] Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S etal. Pre-B cell colony-enhancing factor/visfatin, a new markerof inflammation in rheumatoid arthritis with proinflammatoryand matrix-degrading activities. Arthritis Rheum 2007;56(9):2829-2839.[PubMed][Crossref]
  • [29] Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-UnzuetaMT, Berja A, Miranda-Filloy JA, de Matias JM et al. Visfatinis not associated with inflammation or metabolic syndromein patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 2010; 28(1):56-62.
  • [30] Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, vanTuyl LH, Nurmohamed MT et al. Treatment-specific changesin circulating adipocytokines: a comparison between tumournecrosis factor blockade and glucocorticoid treatment forrheumatoid arthritis. Ann Rheum Dis 2012; 71(9):1510-1516.[Crossref][PubMed]
  • [31] Ferraz-Amaro I, Arce-Franco M, Muniz J, Lopez-Fernandez J,Hernandez-Hernandez V, Franco A et al. Systemic blockadeof TNF-alpha does not improve insulin resistance in humans.Horm Metab Res 2011; 43(11):801-808.
  • [32] Rho YH, Chung CP, Solus JF, Raggi P, Oeser A, GebretsadikT et al. Adipocytokines, insulin resistance, and coronaryatherosclerosis in rheumatoid arthritis. Arthritis Rheum 2010;62(5):1259-1264.[Crossref][PubMed]
  • [33] Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, PalluS et al. Differential distribution of adipokines between serumand synovial fluid in patients with osteoarthritis. Contributionof joint tissues to their articular production. OsteoarthritisCartilage 2006; 14(7):690-695.[PubMed][Crossref]
  • [34] Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, TopleyN, Williams AS et al. Regulation of pre-B cell colonyenhancingfactor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoidarthritis. Arthritis Rheum 2006; 54(7):2084-2095.
  • [35] Meier FM, Frommer KW, Peters MA, Brentano F, Lefevre S,Schroder D et al. Visfatin/pre-B-cell colony-enhancing factor(PBEF), a proinflammatory and cell motility-changing factor inrheumatoid arthritis. J Biol Chem 2012; 287(34):28378-28385.
  • [36] Jurcovicova J, Stofkova A, Skurlova M, Baculikova M, ZoradS, Stancikova M. Alterations in adipocyte glucose transporterGLUT4 and circulating adiponectin and visfatin in rat adjuvantinduced arthritis. Gen Physiol Biophys 2010; 29(1):79-84.[Crossref]
  • [37] Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F,Galli M et al. Pharmacological inhibition of nicotinamidephosphoribosyltransferase/visfatin enzymatic activityidentifies a new inflammatory pathway linked to NAD. PLoSOne 2008; 3(5):e2267.[Crossref]
  • [38] Presumey J, Courties G, Louis-Plence P, Escriou V, SchermanD, Pers YM et al. Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediatesarthritis pathogenesis. Ann Rheum Dis 2013.[PubMed]
  • [39] Chen WP, Bao JP, Feng J, Hu PF, Shi ZL, Wu LD. Increasedserum concentrations of visfatin and its production bydifferent joint tissues in patients with osteoarthritis. Clin ChemLab Med 2010; 48(8):1141-1145.[PubMed]
  • [40] Duan Y, Hao D, Li M, Wu Z, Li D, Yang X et al. Increasedsynovial fluid visfatin is positively linked to cartilagedegradation biomarkers in osteoarthritis. Rheumatol Int2012; 32(4):985-990.[PubMed][Crossref]
  • [41] Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, TahiriK et al. Crucial role of visfatin/pre-B cell colony-enhancingfactor in matrix degradation and prostaglandin E2 synthesisin chondrocytes: possible influence on osteoarthritis. ArthritisRheum 2008; 58(5):1399-1409.
  • [42] Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation ofcartilage-specific gene expression in human chondrocytesby SirT1 and nicotinamide phosphoribosyltransferase. J BiolChem 2008; 283(52):36300-36310.
  • [43] Yammani RR, Loeser RF. Extracellular nicotinamidephosphoribosyltransferase (NAMPT/visfatin) inhibits insulinlikegrowth factor-1 signaling and proteoglycan synthesisin human articular chondrocytes. Arthritis Res Ther 2012;14(1):R23.[Crossref]
  • [44] Jacques C, Holzenberger M, Mladenovic Z, Salvat C,Pecchi E, Berenbaum F et al. Proinflammatory actions ofvisfatin/nicotinamide phosphoribosyltransferase (Nampt)involve regulation of insulin signaling pathway and Namptenzymatic activity. J Biol Chem 2012; 287(18):15100-15108.
  • [45] Chauffier K, Laiguillon MC, Bougault C, Gosset M, PriamS, Salvat C et al. Induction of the chemokine il-8/kc by thearticular cartilage: possible influence on osteoarthritis. JointBone Spine 2012; 79(6):604-609.[PubMed][Crossref]
  • [46] McNulty AL, Miller MR, O’Connor SK, Guilak F. The effects ofadipokines on cartilage and meniscus catabolism. ConnectTissue Res 2011; 52(6):523-533.[PubMed][Crossref]
  • [47] Hong EH, Yun HS, Kim J, Um HD, Lee KH, Kang CM etal. Nicotinamide phosphoribosyltransferase is essentialfor interleukin-1beta-mediated dedifferentiation of articularchondrocytes via SIRT1 and extracellular signal-regulatedkinase (ERK) complex signaling. J Biol Chem 2011;286(32):28619-28631.
  • [48] Gandhi R, Takahashi M, Virtanen C, Syed K, Davey JR,Mahomed NN. Microarray analysis of the infrapatellar fat padin knee osteoarthritis: relationship with joint inflammation. JRheumatol 2011; 38(9):1966-1972.[Crossref]
  • [49] Klein-Wieringa IR, Kloppenburg M, Bastiaansen-JenniskensYM, Yusuf E, Kwekkeboom JC, El-Bannoudi H et al. Theinfrapatellar fat pad of patients with osteoarthritis has aninflammatory phenotype. Ann Rheum Dis 2011; 70(5):851-857.[Crossref]
  • [50] De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV,Rivas L. Serum adipokine levels in patients with systemiclupus erythematosus. Autoimmunity 2009; 42(4):272-274.[Crossref][PubMed]
  • [51] Chung CP, Long AG, Solus JF, Rho YH, Oeser A, RaggiP et al. Adipocytokines in systemic lupus erythematosus:relationship to inflammation, insulin resistance and coronaryatherosclerosis. Lupus 2009; 18(9):799-806.[PubMed][Crossref]
  • [52] Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, CoppolinoG, Amoroso A et al. Adipokines and systemic lupuserythematosus: relationship with metabolic syndrome andcardiovascular disease risk factors. J Rheumatol 2009;36(2):295-297.[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.